Immunic appoints Jason Tardio as COO/President and promotes Werner Gladdines to CDO

IMMUNIC, INC.

Jason Tardio, former Novartis MS franchise head and Biogen exec, appointed COO and President effective July 12, 2024.
Tardio will lead launch preparedness for vidofludimus calcium (IMU-838) and partnership efforts.
Compensation: $500,000 base salary, up to 40% bonus, $120,000 signing bonus, and 500,000 stock options with 4-year vest.
Werner Gladdines promoted from VP to Chief Development Officer, overseeing clinical operations.
Phase 2 CALLIPER trial in progressive MS readout expected April 2025; phase 3 ENSURE trials in relapsing MS due 2026.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jason Tardio

Chief Operating Officer and President

IMUX · IMMUNIC, INC.

Effective: 2024-07-12
Filed: July 9, 2024, 7:59 PM ET

appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024.

Role change

Werner Gladdines

Chief Development Officer

IMUX · IMMUNIC, INC.

Filed: July 9, 2024, 7:59 PM ET

promotion of Werner Gladdines from Vice President, Program Management & Clinical Development Operations to Chief Development Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Tardio was appointed as Chief Operating Officer and President at IMMUNIC, INC..

Action: appointed
Role: Chief Operating Officer and President

Exact text from the filing

appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Werner Gladdines changed role as Chief Development Officer at IMMUNIC, INC..

Action: promoted
Role: Chief Development Officer

Exact text from the filing

promotion of Werner Gladdines from Vice President, Program Management & Clinical Development Operations to Chief Development Officer of the Company.

View on SEC.gov

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-24-000893

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.